Stay updated with breaking news from Rna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) traded up 5% during mid-day trading on Thursday . The stock traded as high as $8.41 and last traded at $8.20. 622,116 shares were traded during mid-day trading, a decline of 42% from the average session volume of 1,076,829 shares. The stock had previously closed […]
In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody oligonucleotide conjugates platform to advance up to five genetic cardiovascular targets. Avidity’s technology, which combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, aims to address the root cause of diseases that are untreatable with current RNA therapeutics. Its lead internal programs are based on the targeted delivery of RNA into muscle.
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo...
When just one of the thousands of microRNAs in people go awry, it can cause diseases ranging from heart disease to cancer.
Avidity's stock soared 30.5% early Tuesday on news of an expanded collaboration with Bristol Myers.